Health Catalyst Inc. officer Benjamin Landry filed a Form 144 notice on November 12, 2026, disclosing a proposed sale of 99,478 shares of common stock executed on November 11, 2026, through Morgan Stanley Smith Barney LLC.
Key Highlights
- Proposed sale: 99,478 shares of Health Catalyst Inc. common stock with an aggregate market value of $143,248.32.
- Seller: Benjamin Landry, identified in the filing as an officer of Health Catalyst Inc.
- Source of shares: Securities were acquired through restricted stock unit vesting, with an acquisition date of February 25, 2026, from the issuer.
- Broker: Morgan Stanley Smith Barney LLC Executive Financial Services, 1 New York Plaza, 8th Floor, New York, NY 10004.
- Prior sales: Landry sold 13,167 shares on September 1, 2026, with gross proceeds of $22,431.30, as disclosed in the past three months' sales section.
- Rule 10b5-1 plan: The filing references a plan adoption date of August 12, 2026.
- Shares outstanding: 76,155,467 shares of common stock outstanding as reported in the filing.
Landry's Proposed Share Sale Under Rule 144 at Health Catalyst
According to the Form 144 filing submitted to the U.S. Securities and Exchange Commission, Benjamin Landry, an officer of Health Catalyst Inc. (NASDAQ:HCAT), provided notice of a proposed sale of 99,478 shares of the company's common stock. The aggregate market value of the shares to be sold is listed as $143,248.32. The approximate date of sale is noted as November 11, 2026, with the filing submitted on November 12, 2026. The filing states that the delay in submission was due to the EDGAR system not accepting filings on November 11, 2026, in observance of a federal holiday.
The filing discloses that the securities to be sold were acquired through restricted stock unit vesting, with the acquisition recorded as February 25, 2026, from the issuer. The remarks section of the filing states: "The securities to be sold were acquired upon the vesting of restricted stock units during the period of 2/25/2026 through 9/1/2026." The filing also indicates that Landry adopted a Rule 10b5-1 trading plan on August 12, 2026.
In the section covering securities sold during the past three months, the filing reports that Landry sold 13,167 shares of common stock on September 1, 2026, generating gross proceeds of $22,431.30. The total shares of Health Catalyst common stock outstanding are listed as 76,155,467. The proposed sale is to be executed through Morgan Stanley Smith Barney LLC Executive Financial Services.
What Was Disclosed
Health Catalyst Inc. officer Benjamin Landry filed a Form 144 notice covering a proposed sale of 99,478 common shares valued at $143,248.32, acquired via restricted stock unit vesting, with sales to be conducted through Morgan Stanley Smith Barney LLC under a Rule 10b5-1 plan adopted August 12, 2026.




Please wait processing your request...